MA32142B1 - Forme cristalline de dérivés de phénylamino pyrimidine - Google Patents

Forme cristalline de dérivés de phénylamino pyrimidine

Info

Publication number
MA32142B1
MA32142B1 MA33147A MA33147A MA32142B1 MA 32142 B1 MA32142 B1 MA 32142B1 MA 33147 A MA33147 A MA 33147A MA 33147 A MA33147 A MA 33147A MA 32142 B1 MA32142 B1 MA 32142B1
Authority
MA
Morocco
Prior art keywords
crystalline form
phenyl amino
pyrimidine derivatives
amino pyrimidine
derivatives
Prior art date
Application number
MA33147A
Other languages
Arabic (ar)
English (en)
Inventor
Amala Kishan Kompella
Sreenivas Rachakonda
Kalisatya Bhujanga Rao Adibhatla
Chowdary Nannapaneni Venkaiah
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/042,247 external-priority patent/US8067422B2/en
Priority claimed from US12/042,235 external-priority patent/US8183253B2/en
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA32142B1 publication Critical patent/MA32142B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme particulière de (3,5-bis trifluorométhyl)-n-[4- méthyl-3-(4-pyridin-3yl-pyrirnidin-2ylamino)-phényl]-benzamide (formule i), ses procédés de préparation, des compositions pharmaceutiques contenant cette forme cristalline et leur utilisation comme agent tumoral chez l'homme. Le composé de la formule (i) est également connu sous le nom de an- 019.
MA33147A 2008-03-04 2010-09-03 Forme cristalline de dérivés de phénylamino pyrimidine MA32142B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/042,247 US8067422B2 (en) 2008-03-04 2008-03-04 Crystal form of phenylamino pyrimidine derivatives
US12/042,235 US8183253B2 (en) 2004-09-09 2008-03-04 Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
PCT/IB2009/005421 WO2009109867A2 (fr) 2008-03-04 2009-03-02 Forme cristalline de dérivés de phénylamino pyrimidine

Publications (1)

Publication Number Publication Date
MA32142B1 true MA32142B1 (fr) 2011-03-01

Family

ID=40802116

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33147A MA32142B1 (fr) 2008-03-04 2010-09-03 Forme cristalline de dérivés de phénylamino pyrimidine

Country Status (18)

Country Link
EP (1) EP2265599B1 (fr)
JP (1) JP2011513380A (fr)
KR (1) KR20100126464A (fr)
CN (1) CN102015681B (fr)
AP (1) AP2651A (fr)
AR (1) AR070783A1 (fr)
AU (1) AU2009220856B2 (fr)
CA (1) CA2716413A1 (fr)
CO (1) CO6300946A2 (fr)
EA (1) EA019223B1 (fr)
GE (1) GEP20135882B (fr)
IL (1) IL207750A0 (fr)
MA (1) MA32142B1 (fr)
MX (1) MX2010009401A (fr)
MY (2) MY183331A (fr)
NZ (1) NZ587518A (fr)
WO (1) WO2009109867A2 (fr)
ZA (1) ZA201005957B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049625A1 (fr) 2009-10-20 2011-04-28 Mansour Samadpour Procédé de criblage d'aflatoxine dans des produits
ES2651682T3 (es) 2009-11-05 2018-01-29 Rhizen Pharmaceuticals S.A. Moduladores de cinasa novedosos
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
US9110310B2 (en) 2011-03-18 2015-08-18 Johnson & Johnson Vision Care, Inc. Multiple energization elements in stacked integrated component devices
CN103702989B (zh) 2011-05-04 2017-07-07 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
KR102216606B1 (ko) 2012-07-04 2021-02-17 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
JP7397491B2 (ja) 2018-10-23 2023-12-13 国立研究開発法人科学技術振興機構 ＰＰＡＲδ活性化剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5184887B2 (ja) * 2004-09-09 2013-04-17 ナトコ ファーマ リミテッド ｂｃｒ−ａｂｌキナーゼの阻害剤としての新規フェニルアミノピリミジン誘導体

Also Published As

Publication number Publication date
EP2265599B1 (fr) 2013-11-20
AU2009220856B2 (en) 2012-07-26
MX2010009401A (es) 2010-09-24
ZA201005957B (en) 2011-10-26
EA019223B1 (ru) 2014-02-28
AR070783A1 (es) 2010-05-05
AU2009220856A2 (en) 2010-09-16
CA2716413A1 (fr) 2009-09-11
JP2011513380A (ja) 2011-04-28
NZ587518A (en) 2012-09-28
GEP20135882B (en) 2013-07-25
WO2009109867A2 (fr) 2009-09-11
IL207750A0 (en) 2010-12-30
MY175373A (en) 2020-06-23
AP2651A (en) 2013-04-25
AP2010005390A0 (en) 2010-10-31
EP2265599A2 (fr) 2010-12-29
KR20100126464A (ko) 2010-12-01
EA201071019A1 (ru) 2011-08-30
CN102015681B (zh) 2013-08-28
CN102015681A (zh) 2011-04-13
AU2009220856A1 (en) 2009-09-11
CO6300946A2 (es) 2011-07-21
MY183331A (en) 2021-02-18
WO2009109867A3 (fr) 2009-12-17

Similar Documents

Publication Publication Date Title
MA32142B1 (fr) Forme cristalline de dérivés de phénylamino pyrimidine
SMT201600267B (it) Inibitori di syk imidazopirazinici
DK2262793T3 (da) Krystallinske former af nilotinib-hci
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
CY1109766T1 (el) Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv
SMT201600275B (it) Composti eterociclici utili come inibitori di pdk1
CY2017042I1 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
JO3067B1 (ar) بيرميدينات بيرازولو امينو كمثبطات ل fak
SMT201700036B (it) Composti e composizioni come inibitori di protein chinasi
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
CR20130369A (es) Novedosos derivados heterocíclicos
DK2389382T3 (da) Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
CR20120121A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso
BR112012006686A2 (pt) composto amida substituído
DK2448938T3 (da) Pyrimidinoner som pi3k-inhibitorer
CO6852067A2 (es) Derivados de 1 -oxo- 1h - ftalazin-2 -ilo comoinhibidores de la tirosina-quinasa de bruton
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
DK3208269T3 (da) Inhibitorer af c-fms-kinase
CR20130419A (es) Derivados heterocíclicos de amina
SMT201400023B (it) Analoghi di buprenorfina
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases